Crossmark

Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy

Crossref DOI link: https://doi.org/10.1038/s41409-025-02674-3

Published Online: 2025-07-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Battista, Marta Lisa https://orcid.org/0009-0007-6602-8021
Facchin, Gabriele https://orcid.org/0000-0002-6695-8954
De Martino, Maria

Chiusolo, Patrizia https://orcid.org/0000-0002-1355-1587
Russo, Domenico

Malagola, Michele https://orcid.org/0000-0003-0907-130X
Saraceni, Francesco https://orcid.org/0000-0001-6500-9514
Mancini, Giorgia

Rambaldi, Alessandro https://orcid.org/0000-0002-3739-7502
Cavattoni, Irene Maria

Lico, Albana

Nozzoli, Chiara

Cuoghi, Angela

Ladetto, Marco

Federico, Vincenzo

Micò, Maria Caterina

Lupo-Stanghellini, Maria Teresa https://orcid.org/0000-0003-1382-6939
Oldani, Elena

Degrandi, Eliana

Gallina, Anna Maria

Parma, Matteo

Biffi, Alessandra https://orcid.org/0000-0002-4610-0870
Fagioli, Franca https://orcid.org/0000-0002-9257-900X
Skert, Cristina

Geromin, Antonella

Savignano, Chiara

Isola, Miriam https://orcid.org/0000-0002-6391-1720
Fanin, Renato

Ciceri, Fabio https://orcid.org/0000-0003-0873-0123
Martino, Massimo https://orcid.org/0000-0002-3987-419X
Patriarca, Francesca https://orcid.org/0000-0002-9813-524X
License Information

Text and Data Mining valid from 2025-07-26

Version of Record valid from 2025-07-26
More Information

Article History

Received: 19 February 2025

Revised: 13 May 2025

Accepted: 24 June 2025

First Online: 26 July 2025

Competing interests

: FP participated in Advisory Board of Menarini, Sanofi, Bristol Meyer Squibb and received lecture honoraria from Johnson&Johnoson and Novartis. MTLS participated in Advisory Board of Novartis, Pfizer, consultancy Incyte, Sanofi, other (organization of scientific event) Therakos / Mallinkrodt. AL participated in AbbVie Speakers Bureau. All other authors declared no potential competing interests in relation to this study.

: Patient and transplant data were extracted from the European PROMISE database and additional queries were then submitted to each center to try to minimize missing data. All patients included in the study provided informed consent to data registration in the PROMISE database. The study, conducted in accordance with good clinical practice guidelines and regulations, was approved by the GITMO Trial Office and by the Institutional Review Board of Udine University (Prot. IRB 145/2024).

Document is current

Any future updates will be listed below